Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease

Pharmacotherapy

Volumn 16, Issue 2 I, 1996, Pages 222-229

  Huang, Eric ^a   Hewitt, Ross G ^b,c   Shelton, Mark ^a,c   Morse, Gene D ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CREATININE; FOSCARNET; GANCICLOVIR; ZALCITABINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADULT; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0029919264     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma creatinme: comparison of five formulae Br J Clin Pharmacol 1989,28:275-80.
2. Rhodes PJ, Rhodes RS, McClelland GH, Culbertson VL, Jahnigen DW, Bloedow DC. Evaluation of eight methods of estimating creatinine clearance in men Clin Pharm 1987;6:399-406.
3. Nicoll SR, Sainsbury R, Bailey RR, et al. Assessment of creatinine clearance in healthy subjects over 65 years of age. Nephron 1991;59:621-5.
4. Smith BL, Sarnoski TP, Dennis S, Luke DR. Failure of predicted creatinine clearance equations in HIV-seropositive patients Int J Clin Pharmacol Ther Toxicol 1992;10:394-9
5. Broder S. Pharmacodynamics of 2′,3′-dideoxycytidine an inhibitor of human immunodeficiency virus Am J Med, 1990;88(suppl 5b):2s-7.
6. King DH. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol 1988;18:176-9.
7. Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokmet 1983,8.187-201.
8. Sjovall J, Karlsson A, Ogenstad S, et al. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988;44:65-73.
9. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother 1989;33(5).742-5
10. Sommadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988;10(suppl 3):s507-14.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Jeliffe RW. Estimation of creatinine clearance when urine cannot be collected Lancet 1971;1:975-6.
13. Jeliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79.604-5.
14. Mawer CE, Knowles BR, Lucas SB, Stirland RA, Tooth JA. Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1972;1:12-15.
15. Hull JH, Hak LJ, Koch GC, Wargin WA, Chi SL, Mattocks AM. Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther 1981;29:516-21
16. Weber JA, van Zanten AP. Interferences in current methods for measurements of creatinine. Clin Chem 1991,37(5):695-700.
17. Devine B. Gentamicin therapy. Drug Intell Clin Pharm 1974,8:650-5.
18. Diem K, Lentner C. Documenta Geigy scientific tables, 7th ed. Ardsley, NY: Ciba-Geigy Corp , 1970:537.
19. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39(5): 489-90.
20. Pesola GR, Akhavan I, Madu A, Shah NK, Carlon GC. Prediction equation estimates of creatmine clearance in the intensive care unit. Intensive Care Med 1993;19:39-43